LeonaBio (LONA) Accumulated Expenses (2019 - 2026)

LeonaBio (LONA) has reported Accumulated Expenses for 8 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 5.36% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (up 5.36% YoY), while the FY2025 annual figure was $1.9 million, down 84.29% from the prior year.
• Accumulated Expenses grew to $4.4 million in Q1 2026 per LONA's latest filing, from $1.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.4 million in Q4 2024 and bottomed at $1.9 million in Q4 2025.
• Historically, Accumulated Expenses has averaged $5.4 million across 5 years, with a median of $4.4 million in 2026.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 1519.87% — and 2025, when it tumbled 84.29%.
• LeonaBio's Accumulated Expenses stood at $8.6 million in 2022, then slumped by 47.18% to $4.5 million in 2023, then surged by 172.87% to $12.4 million in 2024, then sank by 84.29% to $1.9 million in 2025, then surged by 127.1% to $4.4 million in 2026.
• Business Quant data shows LONA's Accumulated Expenses at $4.4 million in Q1 2026, $1.9 million in Q4 2025, and $2.1 million in Q3 2025.